– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies – – iBio Plans to Continue Development of IBIO-200, its Virus-Like Particle Platform – NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has selected IBIO-201, its LicKM™-Subunit …
IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. iBio is …
Chancellor Sharp praises partnership between university, biotech firm COLLEGE STATION, Texas — A team of scientists at Texas A&M is working on two COVID-19 vaccine candidates that could be mass produced quickly in modified tobacco plants. The team is led by Dr. James Samuel, a regents’ professor and the head of the Department of Microbial …
iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that IBM Watson Health has selected iBio to receive 18 months of use of the IBM Clinical Development …
IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies with the potential for rapid manufacturing scale-up in iBio’s FastPharming SystemTM NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced initiation …